This trial is testing a new cancer treatment to see if it is safe and effective.
3 Primary · 11 Secondary · Reporting Duration: From first documented response to confirmed progressive disease or death; approximate duration of 4 years.
4 Treatment Groups
Dose Escalation Part A: NSCLC Immuno-oncology (IO) acquired or primary resistanc...
1 of 4
Dose Escalation Part A: Non small cell lung cancer (NSCLC) Immuno-oncology (IO) ...
1 of 4
Dose Expansion Part B2: NSCLC IO naive
1 of 4
Dose Expansion Part B1: NSCLC IO acquired resistance
1 of 4
81 Total Participants · 4 Treatment Groups
Primary Treatment: AZD7789 · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18 - 130 · All Participants · 19 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there any vacancies open to participants in this clinical trial?
"Affirmative. The information located on clinicaltrials.gov implies that this medical trial is in the process of enrolling participants. It was initially published on September 28th 2021 and most recently updated on November 17th 2022; with 81 patients to be enrolled from 4 different locations." - Anonymous Online Contributor
Is this trial open to participants of the geriatric age range?
"According to the requirements, individuals between 18 and 130 years old can apply for this medical research. There are 21 trials specifically designed for a younger cohort while 1358 studies target elderly patients." - Anonymous Online Contributor
What benefits are anticipated from this research?
"According to AstraZeneca, the clinical trial's primary endpoint is evaluating the anti-tumour activity of AZD7789 over a span of 18 months. Additionally, secondary endpoints such as duration of response, immunogenicity and pharmacokinetic measurements will also be evaluated." - Anonymous Online Contributor
How many participants are included in this clinical experiment?
"Affirmative, according to clinicaltrials.gov the trial posted on September 28th 2021 is currently in progress. The most recent update was made on November 17th 2022 and 81 participants are hoped to be recruited from 4 different medical locations." - Anonymous Online Contributor
Are any locations in North America hosting this experiment?
"At the moment, 4 sites are taking on participants in this trial; Toronto, New York and Nashville being a few of them. To limit travelling needs during your involvement, select the closest site possible to you." - Anonymous Online Contributor
Is it possible to join this research program?
"This clinical trial is currently recruiting 81 individuals with carcinoma, non-small cell lung. To be eligible for the study, participants must meet the following criteria: age between 18 and 130; histologically or cytologically documented Stage IIIB to IV NSCLC that cannot be cured by surgery or radiation; ECOG performance status of 0 or 1; not pregnant (women) and willing to avoid pregnancy (or men willing to use highly effective contraception); adequate organ and bone marrow function measured within 28 days before first dose; squamous/non-squamous NSCLC diagnoses accepted but at least one prior line of systemic therapy containing approved PD" - Anonymous Online Contributor